Pharmacological management of Peyronie's disease

Drugs

Volumn 67, Issue 4, 2007, Pages 527-545

  Trost, Landon W ^a   Gur, Serap ^a   Hellstrom, Wayne J G ^a  

^a TULANE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 AMINOPROPIONITRILE; 4 AMINOBENZOATE POTASSIUM; ALPHA TOCOPHEROL; ALPHA2A INTERFERON; ALPHA2B INTERFERON; BETAMETHASONE; BIOLOGICAL PRODUCT; COLCHICINE; COLLAGENASE; CORTICOSTEROID; DEXAMETHASONE; HYDROCORTISONE; IBUPROFEN; IMMUNOGLOBULIN G; LEVACECARNINE; LIDOCAINE; NONSTEROID ANTIINFLAMMATORY AGENT; PROPOLEUM; SUPEROXIDE DISMUTASE; TAMOXIFEN; TOCOPHEROL; TRIAMCINOLONE HEXACETONIDE; UNCLASSIFIED DRUG; VERAPAMIL;

AGRANULOCYTOSIS; ANOREXIA; ANXIETY; APLASTIC ANEMIA; ARTHRALGIA; ATROPHY; BLOOD VESSEL RUPTURE; BLURRED VISION; BONE MARROW DEPRESSION; CHILL; CLINICAL TRIAL; COLD SWEAT; CONFUSION; COROPORAL RUPTURE; DEPRESSION; DIARRHEA; DISEASE COURSE; DIZZINESS; DRUG EFFICACY; DRUG MECHANISM; DRUG PENETRATION; DRUG SAFETY; DRUG TOLERABILITY; DYSESTHESIA; ECCHYMOSIS; EDEMA; ERYTHEMA; FATIGUE; FEVER; FLU LIKE SYNDROME; GENETIC PREDISPOSITION; GENETIC SUSCEPTIBILITY; HEADACHE; HUMAN; HYPERCALCEMIA; INJECTION SITE PAIN; MENTAL CONCENTRATION; MYALGIA; NAUSEA; NEURITIS; NONHUMAN; PAIN; PATHOPHYSIOLOGY; PENILE PAIN; PENIS PROSTHESIS; PERIPHERAL EDEMA; PEYRONIE DISEASE; PLASTIC SURGERY; PRURITUS; RASH; REVIEW; RIGIDITY; RISK FACTOR; SIDE EFFECT; SINUSITIS; SKIN EDEMA; SKIN IRRITATION; SKIN PRURITUS; SKINFOLD THICKNESS; THROMBOCYTOPENIA; TISSUE ATROPHY; VOMITING; WEAKNESS;

4-AMINOBENZOIC ACID; CONTROLLED CLINICAL TRIALS; HUMANS; INJECTIONS, INTRALESIONAL; MALE; PENILE INDURATION; VITAMIN B COMPLEX; VITAMIN E;

EID: 33947324980     PISSN: 00126667     EISSN: 00126667     Source Type: Journal    
DOI: 10.2165/00003495-200767040-00004     Document Type: Review

References (82)

1. Williams JL, Thomas GG. The natural history of Peyronie's disease. J Urol 1970 Jan; 103 (1): 75-6
2. Gelbard MK, Dorey F, James K. The natural history of Peyronie's disease. J Urol 1990 Dec; 144 (6): 1376-9
3. Kadioglu A, Tefekli A, Erol B, et al. A retrospective review of 307 men with Peyronie's disease. J Urol 2002 Sep; 168 (3): 1075-9
4. Schwarzer U, Sommer F, Klotz T, et al. The prevalence of Peyronie's disease: results of a large survey. BJU Int 2001 Nov; 88 (7): 727-30
5. Mulhall JP, Creech SD, Boorjian SA, et al. Subjective and objective analysis of the prevalence of Peyronie's disease in a population of men presenting for prostate cancer screening. J Urol 2004 Jun; 171 (6 Pt 1): 2350-3
6. Mulhall JP, Schiff J, Guhring P. An analysis of the natural history of Peyronie's disease. J Urol 2006 Jun; 175 (6): 2115-8; discussion 2118
7. Bjekic MD, Vlajinac HD, Sipetic SB, et al. Risk factors for Peyronie's disease: a case-control study. BJU Int 2006 Mar; 97 (3): 570-4
8. Devine CJ Jr, Somers KD, Jordan SG, et al. Proposal: trauma as the cause of the Peyronie's lesion. J Urol 1997 Jan; 157 (1): 285-90
9. Zargooshi J. Trauma as the cause of Peyronie's disease: penile fracture as a model of trauma. J Urol 2004 Jul; 172 (1): 186-8
10. Qian A, Meals RA, Rajfer J, et al. Comparison of gene expression profiles between Peyronie's disease and Dupuytren's contracture. Urology 2004 Aug; 64 (2): 399-404
11. Magee TR, Qian A, Rajfer J, et al. Gene expression profiles in the Peyronie's disease plaque. Urology 2002 Mar; 59 (3): 451-7
12. Davila HH, Ferrini MG, Rajfer J, et al. Fibrin as an inducer of fibrosis in the tunica albuginea of the rat: a new animal model of Peyronie's disease. BJU Int 2003 Jun; 91 (9): 830-8
13. Haag SM, Hauck EK, Szardening-Kirchner C, et al. Alterations in the transforming growth factor (TGF)-beta pathway as a potential factor in the pathogenesis of Peyronie's disease. Eur Urol 2007; 51 (1): 255-61
14. Davila HH, Magee TR, Zuniga FI, et al. Peyronie's disease associated with increase in plasminogen activator inhibitor in fibrotic plaque. Urology 2005 Apr; 65 (4): 645-8
15. Levine LA, Greenfield JM. Establishing a standardized evaluation of the man with Peyronie's disease. Int J Impot Res 2003; 15 (5 Suppl.): 103-2S
16. Rosen RC, Riley A, Wagner G, et al. The international index of erectile function (IIEF): a multidimensional scale for assessment of erectile dysfunction. Urology 1997 Jun; 49 (6): 822-30
17. Kendirci M, Hellstrom WJ. Critical analysis of surgery for Peyronie's disease. Curr Opin Urol 2004 Nov; 14 (6): 381-8
18. Traber MG. Vitamin E. In: Shils ME, Olson JA, Shike M, et al., editors. Modern nutrition in health and disease. 10th ed. Baltimore (MD): Williams & Wilkins, 1999: 347-62
19. Ahuja SK, Sikka SC, Hellstrom WJ. Stimulation of collagen production in an in vitro model for Peyronie's disease. Int J Impot Res 1999 Aug; 11 (4): 207-12
20. Scardino PL, Scott WW. The use of tocopherols in the treatment of Peyronie's disease. Ann NY Acad Sci 1949; 52: 390-401
21. Pryor JP, Farrell CF. Controlled clinical trial of vitamin E in Peyronie's disease. Prog Reprod Biol 1983; 9: 41-5
22. Hashimoto K, Hisasue S, Kato R, et al. Outcome analysis for conservative management of Peyronie's disease. Int J Urol 2006 Mar; 13 (3): 244-7
23. Zarafonetis CJD, Horrax TM. Treatment of Peyronie's disease with potassium para-aminobenzoate (Potaba). J Urol 1959; 81: 770-2
24. Weidner W, Hauck EW, Schnitker J. Potassium paraaminobenzoate (POTABA) in the treatment of Peyronie's disease: a prospective, placebo-controlled, randomized study. Eur Urol 2005 Apr; 47 (4): 530-5; discussion E535-6
25. Hauck EW, Bschleipfer T, Haag SM, et al. Assessment among German urologists of various conservative treatment modalities for Peyronie's disease: results of a survey [in German]. Urologe A 2005; 44: 1189-96
26. El-Sakka AI, Bakircioglu ME, Bhatnagar RS, et al. The effects of colchicine on a Peyronie's-like condition in an animal model. J Urol 1999 Jun; 161 (6): 1980-3
27. Kadioglu A, Tefekli A, Koksal T, et al. Treatment of Peyronie's disease with oral colchicine: long-term results and predictive parameters of successful outcome. Int J Impot Res 2000 Jun; 12 (3): 169-75
28. Prieto Castro RM, Leva Vallejo ME, Requeiro JC, et al. Combined treatment with vitamin E and colchicine in the early stages of Peyronie's disease. BJU Int 2003 Apr; 91 (6): 522-4
29. Safarinejad MR. Therapeutic effects of colchicine in the management of Peyronie's disease: a randomized double-blind, placebo-controlled study. Int J Impot Res 2004 Jun; 16 (3): 238-43
30. Ralph DJ, Brooks MD, Bottazzo GF, et al. The treatment of Peyronie's disease with tamoxifen. Br J Urol 1992 Dec; 70 (6): 648-51
31. Teloken C, Rhoden EL, Grazziotin TM, et al. Tamoxifen versus placebo in the treatment of Peyronie's disease. J Urol 1999 Dec; 162 (6): 2003-5
32. Lemourt OM, Filgueiras LE, Rodriguez BA, et al. Clinical evaluation of the use of propoleum in Peyronie's disease [in Spanish]. Arch Esp Urol 1998; 51: 171-6
33. Lemourt OM, Rodriguez BA, Puente GM, et al. Propoleum and Peyronie's disease [in Spanish]. Arch Esp Urol 2003; 56: 805-13
34. Biagiotti G, Cavallini G. Acetyl-L-carnitine vs tamoxifen in the oral therapy of Peyronie's disease: a preliminary report. BJU Int 2001 Jul; 88 (1): 63-7
35. Tranchant C, Braun S, Warter JM. Mechanism of action of glucocorticoids: role of lipocortins [in French]. Rev Neurol 1989; 145: 813-8
36. Bodner H, Howard AH, Kaplan JH. Peyronie's disease; cortisone- hyaluronidase-hydrocortisone therapy. Trans West Sect Am Urol Assoc 1953; 20: 32-5
37. Winter CC, Khanna R. Peyronie's disease: results with dermo-jet injection of dexamethasone. J Urol 1975 Dec; 114 (6): 898-900
38. Williams G, Green NA. The non-surgical treatment of Peyronie's disease. Br J Urol 1980 Oct; 52 (5): 392-5
39. Cipollone G, Nicolai M, Mastroprimiano G, et al. Betamethasone versus placebo in Peyronie's disease [in Italian]. Arch Ital Urol Androl 1998; 70: 165-8
40. Bartsch G, Menander-Huber KB, Huber W, et al. Orgotein, a new drug for the treatment of Peyronie's disease. Eur J Rheumatol Inflamm 1981; 4 (2): 250-9
41. Gustafson H, Johansson B, Edsmyr F. Peyronie's disease: experience of local treatment with orgotein. Eur Urol 1981; 7 (6): 346-8
42. Revelli G, Marino B, Piccoli F, et al. La Peyronie's disease: our experience [in Italian]. Minerva Chir 1990; 45: 47-50
43. Primus G. Orgotein in the treatment of plastic induration of the penis (Peyronie's disease). Int Urol Nephrol 1993; 25 (2): 169-72
44. Uthman I, Raynauld JP, Haraoui B. Intra-articular therapy in osteoarthritis. Postgrad Med J 2003; 79: 449-53
45. Gelbard M, Walsh R, Kaufman JJ. Clostridial collagenase and Peyronie disease [letter]. Urology 1980 May; 15 (5): 536
46. Gelbard MK, Lindner A, Kaufman JJ. The use of collagenase in the treatment of Peyronie's disease. J Urol 1985 Aug; 134 (2): 280-3
47. Gelbard MK, James K, Riach P, et al. Collagenase versus placebo in the treatment of Peyronie's disease: a double-blind study. J Urol 1993 Jan; 149 (1): 56-8
48. Hamilton RG, Mintz GR, Gelbard MK: Humoral immune responses in Peyronie's disease patients receiving clostridial collagenase therapy. J Urol 1986 Mar; 135 (3): 641-7
49. Roth M, Eickelberg O, Kohler E, et al. Ca2+ channel blockers modulate metabolism of collagens within the extracellular matrix. Proc Natl Acad Sci USA 1996; 93: 5478-82
50. Mulhall JP, Anderson MS, Lubrano T, et al. Peyronie's disease cell culture models: phenotypic, genotypic and functional analyses. Int J Impot Res 2002; 14: 397-405
51. Levine LA, Merrick PF, Lee RC. Intralesional verapamil injection for the treatment of Peyronie's disease. J Urol 1994 Jun; 151 (6): 1522-4
52. Arena F, Peracchia G, Di Stefano C, et al. Clinical effects of verapamil in the treatment of Peyronie's disease [in Italian]. Acta Biomed Ateneo Parmense 1995; 66: 269-72
53. Lasser A, Vandenberg TL, Vincent MJ, et al. Intraplaque verapamil injection for treatment of Peyronie's disease. J La State Med Soc 1998 Sep; 150 (9): 431-4
54. Levine LA, Goldman KE, Greenfield JM. Experience with intraplaque injection of verapamil for Peyronie's disease. J Urol 2002 Aug; 168 (2): 621-5; discussion 625-6
55. Rehman J, Benet A, Melman A. Use of intralesional verapamil to dissolve Peyronie's disease plaque: a long-term single-blind study. Urology 1998 Apr; 51 (4): 620-6
56. Duncan MR, Berman B, Nseyo UO. Regulation of the proliferation and biosynthetic activities of cultured human Peyronie's disease fibroblasts by interferons-alpha, -beta and -gamma. Scand J Urol Nephrol 1991; 25 (2): 89-94
57. Wegner HE, Andresen R, Knipsel HH, et al. Treatment of Peyronie's disease with local interferon-alpha 2b. Eur Urol 1995; 28 (3): 236-40
58. Ahuja S, Bivalacqua TJ, Case J, et al. A pilot study demonstrat-ing clinical benefit from intralesional interferon alpha 2B in the treatment of Peyronie's disease. J Androl 1999 Jul-Aug; 20 (4): 444-8
59. Brake M, Loertzer H, Horsch R, et al. Treatment of Peyronie's disease with local interferon-alpha 2b. BJU Int 2001 May; 87 (7): 654-7
60. Astorga R, Cantero O, Contreras D, et al. Intralesional recombinant interferon alpha-2b in Peyronie's disease. Arch Esp Urol. 2000 Sep; 53 (7): 665-71
61. Judge IS, Wisniewski ZS. Intralesional interferon in the treatment of Peyronie's disease: a pilot study. Br J Urol 1997 Jan; 79 (1): 40-2
62. Polat O, Gul O, Ozbey I, et al. Peyronie's disease: intralesional treatment with interferon alpha-2A and evaluation of the results by magnetic resonance imaging. Int Urol Nephrol 1997; 29 (4): 465-71
63. Dang G, Matern R, Bivalacqua TJ, et al. Intralesional interferon-alpha-2B injections for the treatment of Peyronie's disease. South Med J 2004 Jan; 97 (1): 42-6
64. Kendirci M, Usta MF, Matern RV, et al. The impact of intralesional interferon alpha-2b injection therapy on penile hemodynamics in men with Peyronie's disease. J Sex Med 2005 Sep; 2 (5): 709-15
65. Hellstrom WJ, Kendirci M, Matern R, et al. Single-blind, multicenter, placebo controlled, parallel study to assess the safety and efficacy of intralesional interferon alpha-2B for minimally Aninvasive treatment for Peyronie's disease. J Urol 2006 Jul; 176 (1): 394-8
66. Wegner HE, Andresen R, Knispel HH, et al. Local interferon-alpha 2b is not an effective treatment in early-stage Peyronie's disease. Eur Urol 1997; 32 (2): 190-3
67. Gelbard M, Lindner A, Chvapil M, et al. Topical beta-aminopropionitrile in the treatment of Peyronie's disease. J Urol 1983; 129 (4): 746-8
68. Miller HC, Ardizzone J. Peyronie disease treated with ultrasound and hydrocortisone. Urology 1983; 21 (6): 584-5
69. Martin DJ, Badwan K, Parker M, et al. Transdermal application of verapamil gel to the penile shaft fails to infiltrate the tunica albuginea. J Urol 2002; 168 (6): 2483-5
70. Schieroni MP, Revello MP, Colombo M, et al. Orgotein iontophoresis in the therapy of induratio penis plastica [in Italian]. Minerva Med 1985; 76 (22-23): 1085-8
71. Levine LA, Estrada CR, Shou W, et al. Tunica albuginea tissue analysis after electromotive drug administration. J Urol 2003; 169 (5): 1775-8
72. Di Stasi SM, Giannantoni A, Stephen RL, et al. A prospective, randomized study using transdermal electromotive administration of verapamil and dexamethasone for Peyronie's disease. J Urol 2004; 171 (4): 1605-8
73. Di Stasi SM, Giannantoni A, Capelli G, et al. Transdermal electromotive administration of verapamil and dexamethasone for Peyronie's disease. BJU Int 2003; 91 (9): 825-9
74. Pryor JP, Fitzpatrick JM. A new approach to the correction of the penile deformity in Peyronie's disease. J Urol 1979 Nov; 122 (5): 622-3
75. Bystrom J, Alfthan O, Gustafson H, et al. Early and late results after excision and dermo-fat grafting for Peyronie's disease. Prog Reprod Biol 1972; 9: 78-84
76. Austoni E, Colombo F, Mantovani F, et al. Chirurgia radicale e conservazione dell'erezione nella malattia di La Peyronie. Arch Ital Urol 1995; 67: 359-64
77. Kadioglu A, Tefekli A, Usta M, et al. Surgical treatment of Peyronie's disease with incision and venous patch technique. Int J Impot Res 1999; 11: 75-81
78. El-Sakka AI, Rashwan HM, Lue TF. Venous patch graft for Peyronie's disease: part II. Outcome analysis. J Urol 1998; 160: 2050-3
79. Valente E, Vernet D, Ferrini M, et al. L-Arginine and phosphodiesterase (PDE) inhibitors counteract fibrosis in the Peyronie's fibrotic plaque and related fibroblast cultures. Nitric Oxide 2003; 9 (4): 229-44
80. Minor TX, Lin G, Jad A, et al. The effect of pentoxifylline on cultured human tunical fibroblasts from patients with Peyronie's disease [online abstract]. Available from URL: http:// peyroniesassociation.org/abstracts/ effests_of_pentoxifylline. html [Accessed 2007 Jan 18]
81. Davila HH, Magee TR, Rajfer J, et al. Gene transfer of inducible nitric oxide synthase complementary DNA regresses the fibrotic plaque in an animal model of Peyronie's disease. Biol Reprod 2004; 71 (5): 1568-77
82. Brant WO, Dean RC, Lue TF. Treatment of Peyronie's disease with oral pentoxifylline. Nat Clin Pract Urol 2006; 3 (2): 111-5